Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that methotrexate combined with low- to moderate-dose oral corticosteroids may effectively treat severe alopecia areata, though long-term maintenance is often necessary due to relapse after tapering.

This study suggests that BTP levels in cerebrospinal fluid might help diagnose CIDP and predict therapy response but require validation in larger cohorts.

This study describes tumor necrosis factor inhibitor-associated psoriatic alopecia, highlighting the distinctive histologic feature of sebaceous lobule atrophy, which is potentially reversible and helps differentiate it from idiopathic psoriatic alopecia.

Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.

In this randomized controlled trial, researchers found that after six months of treatment, oral baricitinib was significantly more effective than methotrexate for improving hair regrowth in patients with severe alopecia areata, as measured by the Severity of Alopecia Tool score.

This study found that Lymphotoxin-beta primarily influences periderm differentiation, impacting epidermal and hair follicle differentiation at later stages.

Phenobarbitone can cause severe and sometimes fatal skin reactions.

This study found that hypogonadism in men can be a reversible risk factor for torsades de pointes (TdP), with testosterone replacement potentially preventing TdP recurrence.

This review discusses the molecular mechanisms and clinical applications of thymosin β4, highlighting its potential benefits for inflammation, wound healing, tumor metastasis, and other medical conditions but reports no new experimental results.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This study observed that overexpression of Bcl-2 in certain transgenic mice accelerates catagen progression and increases hair follicle apoptosis and alopecia, while Bcl-2 deficient mice show delayed hair growth and pigmentation changes.

Tailored medication preparation and ongoing education are crucial for effective treatments.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This study found that thyroxine modulates peripheral molecular clock gene expression in human hair follicles, which may have implications for treating clock-related diseases in patients with thyroid dysfunction.

This study found that mimicking the XPD point mutation in mice resulted in trichothiodystrophy-like symptoms, supporting the role of basal transcription and DNA repair defects in the disease.

Baricitinib helps regrow hair in teens with severe alopecia areata.

This commentary discusses the feasibility and challenges of uterine transplantation for transgender women, emphasizing anatomical, hormonal, and ethical considerations without reporting new clinical results.

This study found that minoxidil sulfate stimulates Cl channels, potentially depolarization-activated and outwardly rectifying, in eccrine clear cells, while minoxidil itself stimulates Ca-insensitive K currents.

In this study, researchers found that estrogens activate and androgens inhibit brown adipose tissue thermogenesis via the VMH, affecting energy balance and suggesting targets for treating cachexia and obesity.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

This study found that applying 2.5% testosterone gel increased facial terminal hairs in young males with beta-thalassemia major and was well tolerated.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This study reported that there are no standardized guidelines for managing testosterone-induced acne vulgaris and androgenic alopecia in transmasculine or non-binary individuals undergoing gender-affirming hormone therapy, highlighting gaps in dermatology trainees’ preparedness to care for this population.

This review discusses the pathogenesis and treatment of acne in transgender men on testosterone therapy and reports no new clinical results, emphasizing the need for tailored guidelines.

This article explores the therapeutic potential of TECAR therapy for physiotherapy, highlighting its non-invasive nature and ability to provide analgesic, anti-inflammatory, and tissue healing effects across various conditions with minimal side effects when applied correctly.

In this report, two adult patients with Tatton-Brown-Rahman syndrome exhibited new cardiac features, such as atrial fibrillation and ventricular and atrial dilatation, highlighting the importance of cardiovascular follow-up in adults with this condition.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.

In this study, researchers identified compound heterozygous variants in the MBTPS1 gene associated with ectodermal dysplasia features in a 14-year-old female, broadening the known disorder spectrum linked to these genetic mutations.